• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MEM
Click for more information
0.00% 0.5¢

MEMPHASYS LIMITED. - Announcements

Market Cap $13.00M  ! watchlist Created with Sketch. Add to my watchlist

Memphasys Limited is an Australia-based reproductive biotechnology company. The Company... Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MEM Rights issue completion and allotment28/03/19
MEM Rights Issue Prospectus shortfallPRICE SENSITIVE26/03/19
MEM Appendix 3B - Rights Issue Prospectus01/03/19
MEM Rights Issue ProspectusPRICE SENSITIVE01/03/19
MEM Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
MEM Entitlement issue and dual listingPRICE SENSITIVE27/02/19
MEM Trading HaltPRICE SENSITIVE25/02/19
MEM FELIX product development and commercialisation update29/01/19
MEM Expiry of unlisted options18/01/19
MEM A FURTHER TWO KEY OPINION LEADERS APPOINTED14/01/19
MEM TWO MORE KEY OPINION LEADERS APPOINTED11/01/19
MEM First USA based KOL appointed to undertake FELIX assessment20/12/18
MEM Cleansing Notice03/12/18
MEM Appendix 3B03/12/18
MEM 2018 AGM - Results of Meeting22/11/18
MEM 2018 AGM Chairman's Address to Shareholders22/11/18
MEM Second KOL appointed to undertake FELIX assessment22/11/18
MEM MEM presentation to the TechInvest Conference30/10/18
MEM Response to ASX aware queryPRICE SENSITIVE23/10/18
MEM First KOL appointed to undertake FELIX assessment22/10/18
MEM Response to ASX price queryPRICE SENSITIVE18/10/18
MEM Pause in tradingPRICE SENSITIVE18/10/18
MEM 2018 Notice of Annual General Meeting/Proxy Form11/10/18
MEM Change in substantial holding - AG05/10/18
MEM Change in substantial holding - AC05/10/18
MEM Change of Director's Interest Notice02/10/18
MEM Change of Director's Interest Notice02/10/18
MEM Change of Director's Interest Notice27/09/18
MEM Change of Director's Interest Notice - MM21/09/18
MEM Collaborative Agreement with Monash IVF GroupPRICE SENSITIVE18/09/18
MEM Felix Development & Commercialisation Update12/09/18
MEM Appendix 3B - options06/09/18
MEM Appendix 4G and corporate governance statement30/08/18
MEM Full Year Statutory Accounts27/08/18
MEM Preliminary Final ReportPRICE SENSITIVE24/08/18
MEM Consolidation update and correction to options16/08/18
MEM Memphasys secures R&D tax refund for FELIX device developmnt16/08/18
MEM Change in substantial holding - Peeters Investments14/08/18
MEM Consolidation of securities and Form 3A.314/08/18
MEM Placement cleansing statement09/08/18
MEM Appendix 3B09/08/18
MEM Consolidation timetable update07/08/18
MEM Results of Meeting of Shareholders06/08/18
MEM Preeminent IVF clinics to conduct in-vitro studies on Felix19/07/18 download Created with Sketch. 223.52KB
MEM Initial Director's Interest Notice13/07/18 download Created with Sketch. 118.13KB
MEM Notice of General Meeting/Proxy Form06/07/18 download Created with Sketch. 243.9KB
MEM Proposed share consolidaitonPRICE SENSITIVE03/07/18 download Created with Sketch. 156.25KB
MEM Non-executive Director Appointment and Resignation07/06/18 download Created with Sketch. 259.92KB
MEM Becoming a substantial holder - Peters Investments01/06/18 download Created with Sketch. 463.28KB
MEM Share Placement Cleansing Notice25/05/18 download Created with Sketch. 159.44KB
MEM Appendix 3B - Peters Investments strategic investment25/05/18 download Created with Sketch. 354.5KB
MEM Memphasys raises $1m via a strategic investmentPRICE SENSITIVE25/05/18 download Created with Sketch. 243.14KB
MEM Felix device development updatePRICE SENSITIVE03/05/18
MEM Settlement of legal dispute with Platinum Rd / Bridge Rd19/03/18
MEM Correction to Placement Offer Cleansing Notice14/03/18
MEM Appendix 3B (correction to 1 March 2018)06/03/18
MEM Cleansing Notice01/03/18
MEM Appendix 3B01/03/18
MEM Appendix 4D - December 2017 Half year Financial AccountsPRICE SENSITIVE23/02/18
MEM Commercialisation Progress of Felix Device22/02/18
MEM Legal action with Platinum Road / Bridge Road CapitalPRICE SENSITIVE13/02/18
MEM Placement s708 cleansing notice02/01/18
MEM Appendix 3B02/01/18
MEM Change of Director's Interest Notice29/12/17
MEM Becoming a substantial holder29/12/17
MEM Change of Director's Interest Notice29/12/17
MEM Change in substantial holding29/12/17
MEM Placement Offer cleansing statement29/12/17
MEM Appendix 3B Placement29/12/17
MEM $400,000 Special Grant received from the NSW Medical DevicesPRICE SENSITIVE22/12/17
MEM Results of General Meeting21/12/17
MEM Non-Renounceable Rights Issue - Shortfall Shares19/12/17
MEM Non-Renounceable Pro-rata Entitlement Offer despatched08/12/17
MEM 2017 Results of Annual General Meeting05/12/17
MEM Chairman's Address to Shareholders05/12/17
MEM Change of Director's Interest Notice29/11/17
MEM Change in substantial holding29/11/17
MEM Appendix 3B - Non-Renounceable Rights Issue28/11/17
MEM MEM Non-Renounceable Rights Issue OfferPRICE SENSITIVE28/11/17
MEM Rights Offer Cleaning NoticePRICE SENSITIVE28/11/17
MEM $400,000 special grant offer from NSW Medical Devices FundPRICE SENSITIVE24/11/17
MEM Share issue price for capital raising22/11/17
MEM Notice of General Meeting/Proxy Form22/11/17
MEM $3.75M Capital Raising to Accelerate Dev of Felix DevicePRICE SENSITIVE21/11/17
MEM Annual Report to shareholders01/11/17
MEM Notice of Annual General Meeting/Proxy Form01/11/17
MEM Advanced development of Felix device supported by R&D rebatePRICE SENSITIVE10/10/17
MEM App4G and Corporate Governance Statement29/09/17
MEM Full Year Statutory Accounts29/09/17
MEM MEM completes PrIME and Manukan settlement action27/09/17
MEM Adjusting amendment to Appendix 4EPRICE SENSITIVE13/09/17
MEM Memphasys settles dispute with Transocean Securities08/09/17
MEM Appendix 4E Preliminary Final ReportPRICE SENSITIVE31/08/17
MEM Memphasys Presentation - update on activities07/08/17
MEM Correction to Outcome of LitigationPRICE SENSITIVE28/07/17
MEM Outcome of LitigationPRICE SENSITIVE27/07/17
MEM Trading HaltPRICE SENSITIVE25/07/17
MEM Cleansing Statement17/07/17
MEM Appendix 3B17/07/17
MEM Felix Project development updatePRICE SENSITIVE13/07/17
MEM Rights issue completion and allotment
28/03/19
MEM Rights Issue Prospectus shortfall
26/03/19PRICE SENSITIVE
MEM Appendix 3B - Rights Issue Prospectus
01/03/19
MEM Rights Issue Prospectus
01/03/19PRICE SENSITIVE
MEM Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
MEM Entitlement issue and dual listing
27/02/19PRICE SENSITIVE
MEM Trading Halt
25/02/19PRICE SENSITIVE
MEM FELIX product development and commercialisation update
29/01/19
MEM Expiry of unlisted options
18/01/19
MEM A FURTHER TWO KEY OPINION LEADERS APPOINTED
14/01/19
MEM TWO MORE KEY OPINION LEADERS APPOINTED
11/01/19
MEM First USA based KOL appointed to undertake FELIX assessment
20/12/18
MEM Cleansing Notice
03/12/18
MEM Appendix 3B
03/12/18
MEM 2018 AGM - Results of Meeting
22/11/18
MEM 2018 AGM Chairman's Address to Shareholders
22/11/18
MEM Second KOL appointed to undertake FELIX assessment
22/11/18
MEM MEM presentation to the TechInvest Conference
30/10/18
MEM Response to ASX aware query
23/10/18PRICE SENSITIVE
MEM First KOL appointed to undertake FELIX assessment
22/10/18
MEM Response to ASX price query
18/10/18PRICE SENSITIVE
MEM Pause in trading
18/10/18PRICE SENSITIVE
MEM 2018 Notice of Annual General Meeting/Proxy Form
11/10/18
MEM Change in substantial holding - AG
05/10/18
MEM Change in substantial holding - AC
05/10/18
MEM Change of Director's Interest Notice
02/10/18
MEM Change of Director's Interest Notice
02/10/18
MEM Change of Director's Interest Notice
27/09/18
MEM Change of Director's Interest Notice - MM
21/09/18
MEM Collaborative Agreement with Monash IVF Group
18/09/18PRICE SENSITIVE
MEM Felix Development & Commercialisation Update
12/09/18
MEM Appendix 3B - options
06/09/18
MEM Appendix 4G and corporate governance statement
30/08/18
MEM Full Year Statutory Accounts
27/08/18
MEM Preliminary Final Report
24/08/18PRICE SENSITIVE
MEM Consolidation update and correction to options
16/08/18
MEM Memphasys secures R&D tax refund for FELIX device developmnt
16/08/18
MEM Change in substantial holding - Peeters Investments
14/08/18
MEM Consolidation of securities and Form 3A.3
14/08/18
MEM Placement cleansing statement
09/08/18
MEM Appendix 3B
09/08/18
MEM Consolidation timetable update
07/08/18
MEM Results of Meeting of Shareholders
06/08/18
MEM Preeminent IVF clinics to conduct in-vitro studies on Felix
19/07/18 download Created with Sketch. 223.52KB
MEM Initial Director's Interest Notice
13/07/18 download Created with Sketch. 118.13KB
MEM Notice of General Meeting/Proxy Form
06/07/18 download Created with Sketch. 243.9KB
MEM Proposed share consolidaiton
03/07/18PRICE SENSITIVE download Created with Sketch. 156.25KB
MEM Non-executive Director Appointment and Resignation
07/06/18 download Created with Sketch. 259.92KB
MEM Becoming a substantial holder - Peters Investments
01/06/18 download Created with Sketch. 463.28KB
MEM Share Placement Cleansing Notice
25/05/18 download Created with Sketch. 159.44KB
MEM Appendix 3B - Peters Investments strategic investment
25/05/18 download Created with Sketch. 354.5KB
MEM Memphasys raises $1m via a strategic investment
25/05/18PRICE SENSITIVE download Created with Sketch. 243.14KB
MEM Felix device development update
03/05/18PRICE SENSITIVE
MEM Settlement of legal dispute with Platinum Rd / Bridge Rd
19/03/18
MEM Correction to Placement Offer Cleansing Notice
14/03/18
MEM Appendix 3B (correction to 1 March 2018)
06/03/18
MEM Cleansing Notice
01/03/18
MEM Appendix 3B
01/03/18
MEM Appendix 4D - December 2017 Half year Financial Accounts
23/02/18PRICE SENSITIVE
MEM Commercialisation Progress of Felix Device
22/02/18
MEM Legal action with Platinum Road / Bridge Road Capital
13/02/18PRICE SENSITIVE
MEM Placement s708 cleansing notice
02/01/18
MEM Appendix 3B
02/01/18
MEM Change of Director's Interest Notice
29/12/17
MEM Becoming a substantial holder
29/12/17
MEM Change of Director's Interest Notice
29/12/17
MEM Change in substantial holding
29/12/17
MEM Placement Offer cleansing statement
29/12/17
MEM Appendix 3B Placement
29/12/17
MEM $400,000 Special Grant received from the NSW Medical Devices
22/12/17PRICE SENSITIVE
MEM Results of General Meeting
21/12/17
MEM Non-Renounceable Rights Issue - Shortfall Shares
19/12/17
MEM Non-Renounceable Pro-rata Entitlement Offer despatched
08/12/17
MEM 2017 Results of Annual General Meeting
05/12/17
MEM Chairman's Address to Shareholders
05/12/17
MEM Change of Director's Interest Notice
29/11/17
MEM Change in substantial holding
29/11/17
MEM Appendix 3B - Non-Renounceable Rights Issue
28/11/17
MEM MEM Non-Renounceable Rights Issue Offer
28/11/17PRICE SENSITIVE
MEM Rights Offer Cleaning Notice
28/11/17PRICE SENSITIVE
MEM $400,000 special grant offer from NSW Medical Devices Fund
24/11/17PRICE SENSITIVE
MEM Share issue price for capital raising
22/11/17
MEM Notice of General Meeting/Proxy Form
22/11/17
MEM $3.75M Capital Raising to Accelerate Dev of Felix Device
21/11/17PRICE SENSITIVE
MEM Annual Report to shareholders
01/11/17
MEM Notice of Annual General Meeting/Proxy Form
01/11/17
MEM Advanced development of Felix device supported by R&D rebate
10/10/17PRICE SENSITIVE
MEM App4G and Corporate Governance Statement
29/09/17
MEM Full Year Statutory Accounts
29/09/17
MEM MEM completes PrIME and Manukan settlement action
27/09/17
MEM Adjusting amendment to Appendix 4E
13/09/17PRICE SENSITIVE
MEM Memphasys settles dispute with Transocean Securities
08/09/17
MEM Appendix 4E Preliminary Final Report
31/08/17PRICE SENSITIVE
MEM Memphasys Presentation - update on activities
07/08/17
MEM Correction to Outcome of Litigation
28/07/17PRICE SENSITIVE
MEM Outcome of Litigation
27/07/17PRICE SENSITIVE
MEM Trading Halt
25/07/17PRICE SENSITIVE
MEM Cleansing Statement
17/07/17
MEM Appendix 3B
17/07/17
MEM Felix Project development update
13/07/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $13.00M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $12.5K 2.5M

Buyers (Bids)

No. Vol. Price($)
4 4139600 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 11066843 9
View Market Depth
Last trade - 15.45pm 29/11/2024 (20 minute delay) ?
Last
0.5¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 200000
Last updated 14.07pm 29/11/2024 ?
MEM (ASX) Chart

Top Stories

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Resolute shares bounce back as second payment made to Mali government to secure workers' release Resolute Mining Ltd has told investors that a second payment has been made to the Mali government following the detention of three employees
Parkes Au-Cu project to 'transform' Adavale Resources with key targets Adavale Resources Ltd has entered into an all-scrip acquisition of the Parkes gold and copper project in New South Wales
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.